利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.034 秒)

    Stem cells of the islets of langerhans and their use in treating diabetes mellitus
    3.
    发明授权
    Stem cells of the islets of langerhans and their use in treating diabetes mellitus 有权
    朗格汉斯胰岛的干细胞及其在治疗糖尿病中的应用

    公开(公告)号：US08110399B2

    公开(公告)日：2012-02-07

    申请号：US11438790

    申请日：2006-05-22

    申请人： Joel F. Habener ,  Henryk Zulewski ,  Melissa K. Thomas ,  Elizabeth J. Abraham ,  Mario Vallejo ,  Colin A. Leech ,  Anna Louise Nolan ,  Andreas Lechner

    发明人： Joel F. Habener ,  Henryk Zulewski ,  Melissa K. Thomas ,  Elizabeth J. Abraham ,  Mario Vallejo ,  Colin A. Leech ,  Anna Louise Nolan ,  Andreas Lechner

    IPC分类号： C12N5/071 ,  A01N63/00 ,  A01N65/00

    CPC分类号： A01K67/0271 ,  A61K35/12 ,  A61K2035/122 ,  C12N5/0678 ,  C12N2500/34 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/335 ,  C12N2510/02

    摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

    摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 Nestin和ABCG2已被鉴定为胰干细胞的分子标记，而细胞角蛋白-19可作为不同类型的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白和/或ABCG2-阳性干细胞并进行培养以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。

    Stem cells of the islets of Langerhans and their use in treating diabetes mellitus
    4.
    发明授权
    Stem cells of the islets of Langerhans and their use in treating diabetes mellitus 有权
    朗格汉斯胰岛的干细胞及其在治疗糖尿病中的应用

    公开(公告)号：US07544510B2

    公开(公告)日：2009-06-09

    申请号：US11410412

    申请日：2006-04-24

    申请人： Joel F. Habener ,  Elizabeth J. Abraham ,  Henryk Zulewski ,  Melissa K. Thomas ,  Mario Vallejo

    发明人： Joel F. Habener ,  Elizabeth J. Abraham ,  Henryk Zulewski ,  Melissa K. Thomas ,  Mario Vallejo

    IPC分类号： C12N5/00 ,  C12N5/06

    CPC分类号： C12N5/0676 ,  A01K67/0271 ,  A61K35/12 ,  A61K2035/122 ,  C12N5/0677 ,  C12N5/0678 ,  C12N2500/34 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/335 ,  C12N2510/02

    摘要： Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

    摘要翻译： 描述了用于治疗I型胰岛素依赖性糖尿病和其它条件的方法和组合物，其使用能够分化成多种胰岛细胞（包括产生胰岛素的β细胞）以及肝细胞的新鉴定的干细胞。 巢蛋白已被鉴定为胰腺干细胞的分子标记，而细胞角蛋白-19可作为不同类别的胰岛导管细胞的标记物。 描述了方法，其中可以从胰岛中分离巢蛋白阳性干细胞并进行培养，以获得进一步的干细胞或假胰岛样结构。 公开了胰腺干细胞离体分化方法。 描述了方法，其中胰腺干细胞可以被分离，扩增和移植到有需要的患者中，同种异体地，异质性或异质性的，以提供丢失或损伤的胰岛素分泌细胞或其他细胞的替代。

    Insulinotropic hormone GLP-1 (7-36) and uses thereof
    10.
    发明授权
    Insulinotropic hormone GLP-1 (7-36) and uses thereof 失效
    胰岛素激素GLP-1（7-36）及其用途

    公开(公告)号：US5614492A

    公开(公告)日：1997-03-25

    申请号：US156800

    申请日：1993-11-23

    申请人： Joel F. Habener

    发明人： Joel F. Habener

    IPC分类号： A61K38/00 ,  A61K38/26 ,  C07K14/605 ,  C07K14/62

    CPC分类号： A61K38/26 ,  C07K14/605 ,  Y10S514/866

    摘要： Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1(7-36) have been found to have insulinotropic activity. The invention pertains to the use of GLP-1(7-36) for the treatment of type II diabetes mellitus.

    摘要翻译： 已经发现胰高血糖素样肽I（GLP-1），特别是GLP-1（7-36）的衍生物具有促胰岛素活性。 本发明涉及GLP-1（7-36）用于治疗II型糖尿病的用途。